World-First Clinical Trial: Remotely Delivered tDCS for Cerebral Palsy

Advancing Non-Invasive Brain Stimulation for Children. A recent world-first clinical trial conducted by the Cerebral Palsy Alliance (CPA) has demonstrated the safety, tolerability, and feasibility of remotely supervised transcranial direct current stimulation (tDCS) for children with cerebral palsy (CP). This exploratory, open-label trial represents a significant step toward making advanced neuromodulation treatments more accessible to families in their own homes. Safety, Tolerability, and Feasibility in the Home. While previous studies have explored the potential of tDCS to improve motor function in CP when combined with rehabilitation therapies, ensuring the safe and correct use of these devices outside a clinical setting is crucial. The trial yielded highly encouraging results across three key areas:. Safety: No serious or unexpected side effects were observed. Mild, temporary sensations such as tingling or itchiness on the scalp were reported, but these ceased immediately once the device was turned off., Tolerability: The 1.5 milliamp electrical current was well tolerated. No participant needed to remove the headgear or stop the stimulation early, and the majority found the headgear comfortable to wear., Feasibility: Caregivers reported that setting up the tDCS device was straightforward, taking an average of just 13 minutes, with setup times decreasing as they gained practice. Minimal adjustments were required to maintain stimulation during the sessions. Looking Ahead: Accessible Treatments. These findings suggest that remotely supervised tDCS is a practical and safe option for families. This supports the growing demand for accessible, home-based treatments and paves the way for larger future studies to investigate the efficacy of combining home-based tDCS with ongoing rehabilitation to improve movement and function in children with CP.